Cargando…
Exploiting invariant NKT cells to promote T-cell responses to cancer vaccines
Invariant natural killer T (iNKT) cells have the capacity to amplify adaptive immune responses by licensing antigen-presenting cells. A simple vaccine consisting of whole tumor cells pulsed with an iNKT-cell agonist efficiently delivers antigens plus adjuvants to endogenous dendritic cells and has p...
Autores principales: | Hunn, Martin K., Hermans, Ian F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Landes Bioscience
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654595/ https://www.ncbi.nlm.nih.gov/pubmed/23734325 http://dx.doi.org/10.4161/onci.23789 |
Ejemplares similares
-
Invariant NKT cells: Killers and conspirators against cancer
por: Bassiri, Hamid, et al.
Publicado: (2013) -
NKT cell adjuvants in therapeutic vaccines against hematological cancers
por: Mattarollo, Stephen R., et al.
Publicado: (2013) -
Humanizing mice for the identification of novel anticancer lipids targeting iNKT cells
por: Wen, Xiangshu, et al.
Publicado: (2013) -
Novel Approaches to Exploiting Invariant NKT Cells in Cancer Immunotherapy
por: Wolf, Benjamin J., et al.
Publicado: (2018) -
Attacking malignant cells that survive therapy: Exploiting immunogenic modulation
por: Hodge, James W, et al.
Publicado: (2013)